Overview
Orexin, also known as hypocretin, is an excitatory neuropeptide discovered in 1998 and produced by neurons located in the lateral hypothalamus and perifornical area. There are two forms, Orexin A and Orexin B, both derived from the precursor protein prepro orexin. Orexin plays a central role in the regulation and maintenance of the sleep-wake cycle and wakefulness. In addition to sleep regulation, it influences feeding behavior, energy expenditure, autonomic function, cardiovascular regulation, neuroendocrine control, cognition, reward pathways, and thermogenesis. Orexin exerts its effects through two G protein-coupled receptors, OX1 and OX2, with differing affinities for Orexin A and B.
Symptoms
Altered orexin levels are associated with distinct clinical manifestations. Low orexin levels are most strongly linked to narcolepsy type 1, characterized by excessive daytime sleepiness, cataplexy, disrupted nighttime sleep, and rapid eye movement sleep abnormalities. Other symptoms related to reduced orexin may include chronic fatigue, impaired alertness, and cognitive dysfunction. Elevated orexin activity may be associated with increased arousal, insomnia, anxiety, hypervigilance, and disturbed sleep patterns. Symptoms vary depending on the underlying neurological, metabolic, or endocrine condition affecting orexin signaling.
Causes
Abnormal orexin levels result from dysfunction of orexin-producing neurons or their regulatory pathways. Low orexin levels may occur due to autoimmune destruction of orexin neurons, hypothalamic tumors or lesions, head trauma, neurodegenerative disorders such as Parkinson’s or Alzheimer’s disease, chronic sleep deprivation, prolonged fasting, or malnutrition. Genetic mutations affecting prepro orexin or orexin receptors may also contribute. Elevated orexin levels may be seen in conditions associated with heightened arousal, such as stress, anxiety, insomnia, hyperthyroidism, binge eating, shift work, jet lag, acute physical activity, or stimulant drug use.
Risk Factors
Risk factors for orexin-related disorders include young age at onset of sleep symptoms, genetic predisposition such as HLA DQB1*06:02 positivity, history of autoimmune disease, neurological injury, or hypothalamic pathology. Individuals with persistent excessive daytime sleepiness, unexplained narcolepsy like symptoms, or treatment-resistant insomnia are at higher risk of orexin imbalance. Diagnostic interpretation may be influenced by the timing of sample collection, technical variability, and the coexistence of other sleep or neurological disorders.
Prevention
There are no specific preventive measures to avoid orexin imbalance, as it is closely linked to neurological and genetic factors. Prevention in a clinical context focuses on early recognition and accurate diagnosis. Measurement of cerebrospinal fluid orexin A levels is considered the gold standard for diagnosing narcolepsy type 1, with values below established reference ranges indicating deficiency. Proper sample collection, careful laboratory handling, and correlation with polysomnography and multiple sleep latency testing improve diagnostic accuracy. Early identification enables appropriate management, including the use of orexin receptor antagonists for insomnia and emerging therapies targeting orexin pathways, helping reduce long term neurological and functional complications.
